

Yutaka Yamamoto

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/549261/publications.pdf>

Version: 2024-02-01

68
papers

1,434
citations

257101

24
h-index

344852

36
g-index

73
all docs

73
docs citations

73
times ranked

2483
citing authors

#	ARTICLE	IF	CITATIONS
1	Trends in adjuvant therapy after breast-conserving surgery for ductal carcinoma in situ of breast: a retrospective cohort study using the National Breast Cancer Registry of Japan. <i>Breast Cancer</i> , 2022, 29, 1-8.	1.3	6
2	Predictive and prognostic significance of BRCAness in HER2-negative breast cancer. <i>Breast Cancer</i> , 2022, 29, 368-376.	1.3	3
3	Cardiac computed tomographyâ€derived myocardial tissue characterization after anthracycline treatment. <i>ESC Heart Failure</i> , 2022, 9, 1792-1800.	1.4	3
4	Switch maintenance endocrine therapy plus bevacizumab after bevacizumab plus paclitaxel in advanced or metastatic oestrogen receptor-positive, HER2-negative breast cancer (BOOSTER): a randomised, open-label, phase 2 trial. <i>Lancet Oncology</i> , The, 2022, 23, 636-649.	5.1	5
5	Longitudinal efficacy and safety of capecitabine and cyclophosphamide as early-line treatment in patients with metastatic breast cancer: A prospective cohort study by the Kyushu Breast Cancer Study Group, Japan.. <i>Annals of Cancer Research and Therapy</i> , 2022, 30, 38-44.	0.1	0
6	Results from the phase 1/2 study of patritumab deruxtecan, a HER3-directed antibody-drug conjugate (ADC), in patients with HER3-expressing metastatic breast cancer (MBC).. <i>Journal of Clinical Oncology</i> , 2022, 40, 1002-1002.	0.8	44
7	Pertuzumab retreatment for HER2â€positive advanced breast cancer: A randomized, openâ€label phase III study (PRECIOUS). <i>Cancer Science</i> , 2022, 113, 3169-3179.	1.7	8
8	Prospective observational study of bevacizumab combined with paclitaxel as first- or second-line chemotherapy for locally advanced or metastatic breast cancer: the JBCRG-C05 (B-SHARE) study. <i>Breast Cancer</i> , 2021, 28, 145-160.	1.3	7
9	Analysis of plasma HER2 copy number in cell-free DNA of breast cancer patients: a comparison with HER2 extracellular domain protein level in serum. <i>Breast Cancer</i> , 2021, 28, 746-754.	1.3	3
10	Abstract PD3-11: A randomized, open-label, phase III trial of pertuzumab re-treatment in HER2-positive, locally advanced/metastatic breast cancer patients previously treated with pertuzumab, trastuzumab, and chemotherapy: The Japan Breast Cancer Research Group-M05 (PRECIOUS) study. , 2021, , .		1
11	Meta-analysis of nanoparticle albumin-bound paclitaxel used as neoadjuvant chemotherapy for operable breast cancer based on individual patient data (JBCRG-S01 study). <i>Breast Cancer</i> , 2021, 28, 1023-1037.	1.3	5
12	Health-Related Quality of Life With Trastuzumab Monotherapy Versus Trastuzumab Plus Standard Chemotherapy as Adjuvant Therapy in Older Patients With HER2-Positive Breast Cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, 2452-2462.	0.8	16
13	Soluble Factors Involved in Cancer Cellâ€Macrophage Interaction Promote Breast Cancer Growth. <i>Anticancer Research</i> , 2021, 41, 4249-4258.	0.5	8
14	Annual report of the Japanese Breast Cancer Registry for 2017. <i>Breast Cancer</i> , 2020, 27, 803-809.	1.3	30
15	Randomized Controlled Trial of Trastuzumab With or Without Chemotherapy for HER2-Positive Early Breast Cancer in Older Patients. <i>Journal of Clinical Oncology</i> , 2020, 38, 3743-3752.	0.8	50
16	Focused issue â€œNeoadjuvant/adjuvant treatment for early breast cancerâ€ Chinese Clinical Oncology, 2020, 9, 26-26.	0.4	0
17	A randomized study comparing docetaxel/cyclophosphamide (TC), 5-fluorouracil/epirubicin/cyclophosphamide (FEC) followed by TC, and TC followed by FEC for patients with hormone receptor-positive HER2-negative primary breast cancer. <i>Breast Cancer Research and Treatment</i> , 2020, 180, 715-724.	1.1	2
18	Clinical imaging for the prediction of neoadjuvant chemotherapy response in breast cancer. <i>Chinese Clinical Oncology</i> , 2020, 9, 31-31.	0.4	19

#	ARTICLE	IF	CITATIONS
19	BRCAness as an Important Prognostic Marker in Patients with Triple-Negative Breast Cancer Treated with Neoadjuvant Chemotherapy: A Multicenter Retrospective Study. <i>Diagnostics</i> , 2020, 10, 119.	1.3	6
20	Neoadjuvant endocrine therapy for estrogen receptor-positive primary breast cancer. <i>Chinese Clinical Oncology</i> , 2020, 9, 30-30.	0.4	2
21	Changes in Recurrence Score by neoadjuvant endocrine therapy of breast cancer and their prognostic implication. <i>ESMO Open</i> , 2019, 4, e000476.	2.0	17
22	Pharmacogenomicâ€“pharmacokinetic study of selective estrogen-receptor modulators with intra-patient dose escalation in breast cancer. <i>Breast Cancer</i> , 2019, 26, 535-543.	1.3	5
23	Validation of the 21-gene test as a predictor of clinical response to neoadjuvant hormonal therapy for ER+, HER2-negative breast cancer: the TransNEOS study. <i>Breast Cancer Research and Treatment</i> , 2019, 173, 123-133.	1.1	77
24	Factors involved in early lenvatinib dose reduction: a retrospective analysis. <i>Medical Oncology</i> , 2018, 35, 19.	1.2	9
25	Clinical significance of plasma cell-free DNA mutations in PIK3CA, AKT1, and ESR1 gene according to treatment lines in ER-positive breast cancer. <i>Molecular Cancer</i> , 2018, 17, 67.	7.9	40
26	Impact of clinical response to neoadjuvant endocrine therapy on patient outcomes: a follow-up study of JFMC34-0601 multicentre prospective neoadjuvant endocrine trial. <i>ESMO Open</i> , 2018, 3, e000314.	2.0	15
27	A randomized, open-label, Phase III trial of pertuzumab retreatment in HER2-positive locally advanced/metastatic breast cancer patients previously treated with pertuzumab, trastuzumab and chemotherapy: the Japan Breast Cancer Research Group-M05 PRECIOUS study. <i>Japanese Journal of Clinical Oncology</i> , 2018, 48, 855-859.	0.6	6
28	Therapeutic predictors of neoadjuvant endocrine therapy response in estrogen receptor-positive breast cancer with reference to optimal gene expression profiling. <i>Breast Cancer Research and Treatment</i> , 2018, 172, 353-362.	1.1	20
29	ESR1 and PIK3CA mutational status in serum and plasma from metastatic breast cancer patients: A comparative study. <i>Cancer Biomarkers</i> , 2018, 22, 345-350.	0.8	5
30	Preface for special issue â€œAdvances in treatment and care in metastatic breast cancerâ€“. <i>Chinese Clinical Oncology</i> , 2018, 7, 22-22.	0.4	1
31	Circulating tumor cells as a prognostic marker for efficacy in the randomized phase III JO21095 trial in Japanese patients with HER2-negative metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2017, 162, 501-510.	1.1	13
32	Lenvatinib, an oral multi-kinases inhibitor, -associated hypertension: Potential role of vascular endothelial dysfunction. <i>Atherosclerosis</i> , 2017, 260, 116-120.	0.4	33
33	Efficacy and safety of low-dose capecitabine plus docetaxel versus single-agent docetaxel in patients with anthracycline-pretreated HER2-negative metastatic breast cancer: results from the randomized phase III JO21095 trial. <i>Breast Cancer Research and Treatment</i> , 2017, 161, 473-482.	1.1	7
34	Comparison of ESR1 Mutations in Tumor Tissue and Matched Plasma Samples from Metastatic Breast Cancer Patients. <i>Translational Oncology</i> , 2017, 10, 766-771.	1.7	29
35	Clinical features of lenvatinib treatment in elderly patients with advanced thyroid cancer. <i>Molecular and Clinical Oncology</i> , 2017, 7, 24-26.	0.4	6
36	Prevalence of ESR1 E380Q mutation in tumor tissue and plasma from Japanese breast cancer patients. <i>BMC Cancer</i> , 2017, 17, 786.	1.1	13

#	ARTICLE	IF	CITATIONS
37	Analysis of <i>ESR1</i> and <i>PIK3CA</i> mutations in plasma cell-free DNA from ER-positive breast cancer patients. <i>Oncotarget</i> , 2017, 8, 52142-52155.	0.8	48
38	High density of CD204 ⁺ positive macrophages predicts worse clinical prognosis in patients with breast cancer. <i>Cancer Science</i> , 2017, 108, 1693-1700.	1.7	83
39	BRCAness and prognosis of triple-negative breast cancer patients treated with neoadjuvant chemotherapy. <i>Journal of Clinical Oncology</i> , 2017, 35, e12111-e12111.	0.8	1
40	Clinical significance of monitoring <i>ESR1</i> mutations in circulating cell-free DNA in estrogen receptor positive breast cancer patients. <i>Oncotarget</i> , 2016, 7, 32504-32518.	0.8	49
41	The Clinical Significance of CD169-Positive Lymph Node Macrophage in Patients with Breast Cancer. <i>PLoS ONE</i> , 2016, 11, e0166680.	1.1	54
42	Fibroblast growth factor receptor-1 protein expression is associated with prognosis in estrogen receptor-positive/human epidermal growth factor receptor-2-negative primary breast cancer. <i>Cancer Science</i> , 2016, 107, 491-498.	1.7	40
43	Docetaxel and cyclophosphamide chemotherapy induced radiation recall phenomenon in a postoperative breast cancer patient: a case report. <i>International Cancer Conference Journal</i> , 2016, 5, 202-205.	0.2	3
44	Clinical significance of the expression of autophagy-associated marker, beclin 1, in breast cancer patients who received neoadjuvant endocrine therapy. <i>BMC Cancer</i> , 2016, 16, 230.	1.1	30
45	Prediction of sentinel lymph node status using single-photon emission computed tomography (SPECT)/computed tomography (CT) imaging of breast cancer. <i>Surgery Today</i> , 2016, 46, 214-223.	0.7	8
46	The Japanese Breast Cancer Society Clinical Practice Guideline for systemic treatment of breast cancer, 2015 edition. <i>Breast Cancer</i> , 2016, 23, 329-342.	1.3	49
47	PRECIOUS: A randomized, open-label phase III trial of pertuzumab retreatment in HER2-positive locally advanced/metastatic breast cancer patients who were previously treated with pertuzumab, trastuzumab, and chemotherapy. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS636-TPS636.	0.8	0
48	Prognostic role of <i>PIK3CA</i> mutations of cell-free DNA in early-stage triple negative breast cancer. <i>Cancer Science</i> , 2015, 106, 1582-1589.	1.7	58
49	Immunohistochemical analysis in ethinylestradiol-treated breast cancers after prior long-term estrogen-deprivation therapy. <i>SpringerPlus</i> , 2015, 4, 108.	1.2	3
50	ANGPTL2 increases bone metastasis of breast cancer cells through enhancing CXCR4 signaling. <i>Scientific Reports</i> , 2015, 5, 9170.	1.6	49
51	Droplet digital polymerase chain reaction assay for screening of <i>ESR1</i> mutations in 325 breast cancer specimens. <i>Translational Research</i> , 2015, 166, 540-553.e2.	2.2	55
52	C6ORF97- <i>ESR1</i> breast cancer susceptibility locus: influence on progression and survival in breast cancer patients. <i>European Journal of Human Genetics</i> , 2015, 23, 949-956.	1.4	25
53	Divisional role of quantitative HER2 testing in breast cancer. <i>Breast Cancer</i> , 2015, 22, 161-171.	1.3	3
54	Evaluating the 21-gene assay Recurrence Score [®] as a predictor of clinical response to 24 weeks of neoadjuvant exemestane in estrogen receptor-positive breast cancer. <i>International Journal of Clinical Oncology</i> , 2014, 19, 607-613.	1.0	54

#	ARTICLE	IF	CITATIONS
55	Clinical significance of pretherapeutic Ki67 as a predictive parameter for response to neoadjuvant chemotherapy in breast cancer; is it equally useful across tumor subtypes?. <i>Surgery</i> , 2014, 155, 927-935.	1.0	45
56	An Integrative Analysis of PIK3CA Mutation, PTEN, and INPP4B Expression in Terms of Trastuzumab Efficacy in HER2-Positive Breast Cancer. <i>PLoS ONE</i> , 2014, 9, e116054.	1.1	28
57	Subsequent endocrine therapy after resistance to ethinylestradiol treatment for the late-stage metastatic breast cancer: A retrospective cohort study.. <i>Journal of Clinical Oncology</i> , 2014, 32, 148-148.	0.8	0
58	Relationship of tumor and stromal autophagy and endocrine responsiveness in breast cancer tissues.. <i>Journal of Clinical Oncology</i> , 2013, 31, 571-571.	0.8	0
59	N-SAS BC06: A phase III study of adjuvant endocrine therapy with or without chemotherapy for postmenopausal breast cancer patients who responded to neoadjuvant letrozole (LET): The New Primary Endocrine-Therapy Origination Study (NEOS).. <i>Journal of Clinical Oncology</i> , 2013, 31, TPS654-TPS654.	0.8	0
60	Prospective observational trial of re-antiestrogen therapy after becoming resistant to ethinylestradiol treatment in hormone-dependent metastatic breast cancer.. <i>Journal of Clinical Oncology</i> , 2013, 31, 161-161.	0.8	4
61	A multicenter phase II trial of the LH-RH analogue and an aromatase inhibitor combination in premenopausal patients with advanced or recurrent breast cancer refractory to an LH-RH analogue with tamoxifen: JMTO BC08-01.. <i>Journal of Clinical Oncology</i> , 2012, 30, 588-588.	0.8	2
62	Association of response to neoadjuvant chemotherapy (NAC) in premenopausal patients with hormone receptor-positive early breast cancer with chemotherapy-induced ovarian function suppression by NAC.. <i>Journal of Clinical Oncology</i> , 2012, 30, e11017-e11017.	0.8	1
63	Nab-paclitaxel for the treatment of breast cancer: efficacy, safety, and approval. <i>OncoTargets and Therapy</i> , 2011, 4, 123.	1.0	67
64	Evaluation of Trastuzumab Without Chemotherapy as a Post-operative Adjuvant Therapy in HER2-positive Elderly Breast Cancer Patients: Randomized Controlled Trial [RESPECT (N-SAS BC07)]. <i>Japanese Journal of Clinical Oncology</i> , 2011, 41, 709-712.	0.6	38
65	Clinicopathological features and treatment strategy for triple-negative breast cancer. <i>International Journal of Clinical Oncology</i> , 2010, 15, 341-351.	1.0	41
66	Clinicopathological analyses of triple negative breast cancer using surveillance data from the Registration Committee of the Japanese Breast Cancer Society. <i>Breast Cancer</i> , 2010, 17, 118-124.	1.3	67
67	Clinical usefulness of high-dose toremifene in patients relapsed on treatment with an aromatase inhibitor. <i>Breast Cancer</i> , 2010, 17, 254-260.	1.3	11
68	Mouse mammary gland reconstitution with extrinsic gene-transferred mammary epithelial cells in vitro and in vivo. <i>Inflammation and Regeneration</i> , 2008, 28, 181-188.	1.5	0